Resolve Biosciences secures US$71m in funding
Molecular cartography company Resolve Biosciences has raised $71m in series B funding co-led by Patient Square Capital, EDBI, Alafi Capital and NRW.BANK as well as other existing investors.
The current Series B financing brings Mohnheim-based Resolve Biosciences financing up to a total of more than $100m. The finance round followed the launch of the German companys platform technology for ultra-high resolution imaging of subcellular, single molecule and spatial biology. Called “spatial omics technology”, these analytical methods combine diverse molecular insights into a whole picture on a section of a cell, tissue or whole (smaller) organism.
In recent months, the workflow has been installed in a growing number of leading European and North American laboratories, including the VIB (Vlaams Instituut voor Biotechnologie) in Belgium, the Novo Nordisk Foundation Center at the University of Copenhagen, the German Cancer Research Center (DKFZ), the Stanford Medicine Department of Genetics and the European Spatial Biology Center in Belgium.
“As we have seen through our services business and more recently through our workflows installed in customer labs, our fully automated molecular mapping platform is setting a new standard for subcellular spatial analysis technology,” said Jason T. Gammack, co-founder and CEO of Resolve Biosciences.
